Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

  title={Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial},
  author={Nicholas A. Di Prospero and Angela Baker and Neal O. Jeffries and Kenneth H. Fischbeck},
  journal={The Lancet Neurology},

Figures and Tables from this paper

Idebenone in Friedreich's ataxia

The neurological function is in general not modified in adult patients, but a dose-dependent effect was demonstrated in young Friedreich's ataxia patients, and idebenone is well tolerated in paediatric and adult patients.

Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia

Combined therapy with idebenone and deferiprone in patients with FDRA indicates a stabilizing effect in neurologic dysfunctions due to an improvement in the kinetic functions, with a worsening of gait and posture scores.

Efficacy and safety of idebenone in the treatment of Friedreich ataxia: a review of early results and future prospects

A Phase III trial has begun in the USA with the goal of assessing the efficacy of idebenone for the treatment of neurologic dysfunction in FRDA.

Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study

It is indicated that idebenone at a dose of 1,350/2,250 mg/day may offer a therapeutic benefit to pediatric FRDA patients by stabilizing the overall neurological function and improving fine motor skills and speech.

IGF-1 in Friedreich’s Ataxia – proof-of-concept trial

Results seem to indicate a benefit of this IGF-1 therapy to neurological functions in FRDA, as changes from baseline on the scale for the assessment and rating of ataxia, and by changes in echocardiogram parameters.

Clinical experience with high-dose idebenone in Friedreich ataxia

The results suggested that treatment with intermediate- and high-dose idebenone had beneficial effects on neurological symptoms, and two phase 3 trials have been initiated, one in the United States with young ambulatory patients and one in Europe without limits on age and disease severity.

Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.

At 24 months, EPI-743 treatment was associated with a statistically significant improvement in neurological function and disease progression relative to a natural history cohort and was demonstrated to be safe and well tolerated.

A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.

Iebenone did not significantly alter neurological function in Friedreich ataxia during the 6-month study, and larger studies of longer duration may be needed to assess the therapeutic potential of drug candidates on neurologicalfunction in Fried reaxia.

A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial

  • D. LynchS. Willi T. Sciascia
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2012
Although A0001 did not alter the Disposition Index, it caused a dose‐dependent improvement in neurologic function, as measured by the Friedreich Ataxia Rating Scale, and longer studies will assess the reproducibility and persistence of neurologic benefit.



Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.

Findings indicate that higher doses of idebenone lead to a proportional increase in plasma levels up to 55 mg/kg per day and that high-dose Idebenone is well-tolerated in patients with FA.

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

There is a good case for giving idebenone continuously in a dose of 5–10 mg/kg/day in patients with Friedreich's ataxia at the onset of hypertrophic cardiomyopathy, as the drug has no serious side effects.

Friedreich's ataxia: idebenone treatment in early stage patients.

Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations and further blind trials with a greater number of patients and higher doses are needed to fully assess the therapeutic potential of idebenone in Friedreich's ataxia.

Heart Hypertrophy and Function Are Improved by Idebenone in Friedreich's Ataxia

An open trial of idebenone (oral supplementation; 5 mg/kg/day) in a large series of FRDA patients and followed their left ventricular mass and function, demonstrating the efficiency of Idebenone in controlling heart hypertrophy in FRDA.

Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.

The results support the view that frataxin is a necessary, albeit non-essential, component of the Fe-S cluster biogenesis, and indicate that Idebenone acts downstream of the primary Fe- S enzyme deficit, and support its utilization for the treatment of FRDA.

Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

In view of the lack of a proven agent to limit or halt the progression of dementia in the elderly, idebenone may warrant consideration in patients with mild cognitive dysfunction on the basis of preliminary evidence of predominantly mild improvement of functional status in some patients and good tolerability.

Oxidative stress in patients with Friedreich ataxia

Oral treatment with 5 mg/kg/day of the antioxidant idebenone for 8 weeks significantly decreased urinary 8OH2'dG concentrations, indicating that 8OH 2'dG may be useful in monitoring therapeutic interventions in patients with FRDA.

Idebenone treatment in Friedreich’s ataxia

Idebenone reduced erythrocyte protoporphyrin IX levels in five of six patients with elevated baseline levels; however, changes did not consistently relate to cardiac improvement.

A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy.

A cellular assay system is developed that discriminates between fibroblasts from FRDA patients and unaffected donors on the basis of their sensitivity to pharmacological inhibition of de novo synthesis of glutathione, and demonstrates for the first time that small-molecule GPX mimetics have potential as a novel treatment strategy for Friedreich Ataxia.

Increased levels of plasma malondialdehyde in Friedreich ataxia.

Several lines of evidence support the hypothesis that similar mechanisms are involved in the human disease, and data from yeast suggest that frataxin deficiency results in mitochondrial dysfunction and free radical damage.